Eli Lilly And Stock Analysis

Eli Stock Analysis Notes

About 85.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.89. Eli Lilly recorded earning per share (EPS) of 23.02. The entity last dividend was issued on the 13th of February 2026. The firm had 2:1 split on the 16th of October 1997. Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. Eli Lilly operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 35000 people. To find out more about Eli Lilly and contact Jacob Naarden at 317 276 2000 or learn more at https://www.lilly.com.

Eli Lilly Investment Alerts

Eli Largest EPS Surprises

View All Earnings Estimates

Eli Lilly Environmental, Social, and Governance (ESG) Scores

Eli Lilly Thematic Classifications

Eli Stock Institutional Investors

Note, although Eli Lilly's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Eli Market Capitalization

The company currently falls under 'Mega-Cap' category with a total capitalization of 965.26 B.

Eli Profitablity

The company has Net Profit Margin of 0.32 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.45 %, which entails that for every 100 dollars of revenue, it generated $0.45 of operating income.

Management Efficiency

Eli Lilly has Return on Asset of 0.1942 % which means that on every $100 spent on assets, it made $0.1942 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 1.0116 %, implying that it generated $1.0116 on every 100 dollars invested. Eli Lilly's management efficiency ratios could be used to measure how well Eli Lilly manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 0.82 in 2026, whereas Return On Tangible Assets are likely to drop 0.14 in 2026. At this time, Eli Lilly's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 59.7 B in 2026, despite the fact that Net Tangible Assets are likely to grow to (538.5 M).

Technical Drivers

As of the 20th of February, Eli Lilly shows the Downside Deviation of 2.23, mean deviation of 1.6, and Coefficient Of Variation of 6534.35. In respect to fundamental indicators, the technical analysis model provides you with a way to check existing technical drivers of Eli Lilly, as well as the relationship between them.

Eli Lilly Price Movement Analysis

Eli Lilly Insider Trading Activities

Eli Lilly Outstanding Bonds

Eli Lilly Predictive Daily Indicators

Eli Lilly Corporate Filings

Eli Lilly Forecast Models

Eli Lilly's time-series forecasting models are one of many Eli Lilly's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Eli Lilly's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Eli Lilly Bond Ratings

Eli Lilly and financial ratings play a critical role in determining how much Eli Lilly have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Eli Lilly's borrowing costs.

Eli Lilly Debt to Cash Allocation

Eli Lilly and has 42.5 B in debt with debt to equity (D/E) ratio of 1.58, which is OK given its current industry classification. Eli Lilly has a current ratio of 1.11, demonstrating that it may not be capable to disburse its financial commitments when the payables are due. Nevertheless, prudent borrowing could serve as an effective mechanism for Eli to finance growth opportunities yielding strong returns.

Eli Lilly Total Assets Over Time

Eli Lilly Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Eli Lilly uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Eli Lilly Debt Ratio

40.0

It appears slightly above 60% of Eli Lilly's assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Eli Lilly's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Eli Lilly, which in turn will lower the firm's financial flexibility.

Eli Lilly Corporate Bonds Issued

Eli Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how Eli Lilly prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Eli shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Eli Lilly. By using and applying Eli Stock analysis, traders can create a robust methodology for identifying Eli entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Eli analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Eli analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Eli Lilly and stock analysis indicators help investors evaluate how Eli Lilly stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Eli Lilly shares will generate the highest return on investment. By understating and applying Eli Lilly stock analysis, traders can identify Eli Lilly position entry and exit signals to maximize returns.

When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.